06 FOREIGN NEWS
The HEALTH | January-February. 2026
Celltrion ' s strategic expansions
CELLTRION, Inc., a prominent global biopharmaceutical company, recently presented its strategic priorities and clinical development updates at the 44th Annual J. P. Morgan Healthcare Conference held in San Francisco.
The company ' s focus was on its innovative drug pipelines, specifically antibody-drug conjugates( ADCs) and multi-specific antibodies( msAbs), alongside plans to expand its manufacturing and research and development( R & D) capabilities in the United States.
Celltrion Chief Executive Officer Jin-Seok Seo, and Senior Executive Vice President Hyuk-Jae Lee outlined the ambitious plan to submit up to 16 investigational new drug( IND) applications by 2028.
This pipeline targets 10 ADCs, 4 mAbs, 1 recombinant protein, and 1 peptide, while the biosimilar segment aims to launch up to 18 products by 2030 and 41 by 2038.
Among the ADC candidates, those aimed at solid tumour cancers received notable attention, particularly CT-P70, CT-P71, and CT-P73, for which IND applications were accepted by the U. S. Food and Drug
|
|
|
|
Administration( FDA) in 2025.
CT-P70, a novel ADC targeting non-small cell lung cancer( NSCLC), recently received Fast Track designation from the FDA, facilitating expedited communication throughout its development and accelerating regulatory review.
Celltrion is also advancing a portfolio of msAbs designed to selectively
|
|
|
target cancer cells, including CT-P72, a tetravalent bispecific antibody targeting human epithelial growth factor receptor 2( HER2) and cluster of differentiation 3( CD3), which received FDA IND approval.
Jin-Seok Seo stated: " We made significant progress and see compelling opportunities ahead."
He highlighted the company ' s
|
transition towards innovative therapeutics based on its established excellence in biosimilars.
" Our expanding pipeline of ADCs and msAbs, grounded in deep antibody expertise, underscores our commitment to delivering meaningful value to patients worldwide."
Healthier choices ahead
LIFESTYLE SHIFT: Novo Nordisk ' s GLP-1 therapy is linked to healthier spending habits, promoting weight management and household well-being.
|
Three-in-one relief
IN a notable advancement for the health and wellness sector, the innovative Life-Space TrioBiotic supplement series launched in Southeast Asia, introducing a groundbreaking " three-in-one " approach to gut health. This new series integrates prebiotics, probiotics, and postbiotics into a single daily dose.
The past decade has seen a remarkable evolution in health and wellness, driven largely by the increasing recognition of probiotics and their role in supporting gut health and general well-being. The market for probiotic products has expanded dramatically, encompassing not only supplements but also functional foods, beverages, and even skincare.
With the global probiotics market forecast to reach USD 140.34 billion by 2031, experts have noted a surge in demand across Asia, spurred by health-conscious consumers seeking efficient solutions to manage the challenges of modern lifestyles, which often result in gut dysbiosis.
Research in recent decades has
GUT GOALS: Life-Space TrioBiotic series launches in Southeast Asia, offering innovative solutions for gut health with a groundbreaking three-in-one formula. underscored the vital importance of the microbiome, a complex ecosystem of trillions of microorganisms predominantly located in the gut, in facilitating immune function, nutrient absorption, and maintaining energy levels.
Disruptions in this balance, often influenced by stress, diet, and sleep patterns prevalent in Southeast Asia, can adversely affect overall health.
The TrioBiotic series aims to meet this urgent need by leveraging the interconnected roles of the three biotics: Probiotics: Live microorganisms crucial for digestive wellness. Prebiotics: Substances that nourish beneficial probiotic bacteria. Postbiotics: Beneficial compounds, such as Short-Chain Fatty Acids( SCFAs), produced by probiotics following the consumption of prebiotics.
The Life-Space TrioBiotic series caters to specific gender needs, featuring two distinct products: Life-Space TrioBiotic for Women: Formulated to support general gut health, digestion, and immunity, with additional benefits for vaginal and urogenital health.
Life-Space TrioBiotic for Men: Designed to enhance gut health, energy levels, and immunity, including components that address male health concerns, such as sperm health.
AT the recent ObesityWeek ® congress in Atlanta, Novo Nordisk unveiled significant findings from a comprehensive analysis of grocery spending involving over 200,000 households.
The study revealed that families with at least one member using Novo Nordisk ' s GLP-1 receptor agonist( RA) for weight management experienced a notable decrease in overall grocery expenditures compared with families not using similar medications.
This reduction was particularly prominent in spending on alcohol and tobacco products.
The implications of these findings suggest a potential correlation between the use of GLP-1 therapy and lower rates of alcohol and tobacco consumption within households.
In Indonesia, where obesity rates are rising alarmingly, nearly one in four adults is now classified as obese or carrying excess abdominal fat, raising concerns about associated health risks such as Type 2 diabetes, hypertension, and heart disease.- The HEALTH